N30 Pharma’s drugs target s-nitrosoglutathione reductase (GSNOR), an enzyme of central importance in human health and disease.
These drugs inhibit GSNOR, the most selective enzyme that breaks down s-nitrosoglutathione (GSNO), a key component of the human body’s pool of bioavailable nitric oxide. GSNO and SNOs are important modulators of inflammation, cell death, organ regeneration, and respiratory, vascular, and gastrointestinal function.
Inhibition of GSNOR increases the levels of endogenous, bioreactive nitric oxide. Modulating GSNOR enzymatic activity is an important new therapeutic strategy for the treatment of major diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and vascular disease.